InMode Ltd, a global leader in energy-based aesthetic treatments, presented its Q2 2024 performance and strategic outlook at the Canaccord Genuity 45th Annual Growth Conference. Despite a $5 million shortfall in Q2 due to U.S. market headwinds, the company reported record growth in Europe and Asia Pacific, resulting in a more balanced revenue mix of 50% U.S. and 50% outside the U.S. The company launched new products including the CO2 laser and Optimus Max to meet demand for combination treatments and is expanding into wellness platforms, such as a device for erectile dysfunction. InMode also announced management and sales team restructuring, with a focus on creating specialized sales roles for different product lines. The company has spent $400 million on share buybacks in the past year, with a total of $500 million over recent years, and is evaluating capital allocation options including dividends, further buybacks, and potential acquisitions in aesthetic and wellness segments. Tariffs are expected to reduce gross margins by 2-3% annually, with mitigation efforts underway.

The article discusses Validea's top-rated healthcare stocks based on Peter Lynch's P/E/Growth Investor model, highlighting three companies: Avantor Inc (AVTR), Inmode Ltd (INMD), and Neurocrine Biosciences Inc (NBIX). Each company is evaluated for its financial metrics, industry relevance, and alignment with Lynch's investment strategy.

Market research company Ipsos announced the acquisition of InMoment’s healthcare division in Germany, expanding its expertise in pharmaceutical and medical technology sectors. The acquisition adds a new competence center in Hamburg, complementing existing locations in Nuremberg, Munich, and Frankfurt. Financial terms were not disclosed, and the move is part of Ipsos’s strategy to strengthen its position in the German healthcare research market.

InMode Ltd (NASDAQ:INMD) participated in the Jefferies 2025 Global Health Conference, discussing its strategic direction amid economic challenges. The company faces mixed financial performance, with growth in Europe and Asia but declining U.S. revenue. Key issues include tariffs on Israeli-made products, a 50/50 revenue mix between the U.S. and international markets, and a $508 million stock buyback over two years. InMode is restructuring sales teams, launching new medical platforms, and exploring M&A in injectables despite recent rejections.

The Non-Destructive Medical Technologies Market is projected to grow at a CAGR of 11.25% from 2025 to 2032, driven by technological advancements, rising demand for non-invasive diagnostics, and chronic disease prevalence. The market is expected to expand from USD 95.74 billion in 2023 to USD 250.0 billion by 2032, with key players investing in AI-driven imaging and portable diagnostic solutions.